Inhibition of Ehrlichia chaffeensis infection by cell-permeable macrocyclic peptides that bind type IV secretion
Mingqun Lin1, Amritendu Koley2, Wenqing Zhang1
1Department of Veterinary Biosciences, The Ohio State University, 1925 Coffey Rd, Columbus, OH 43210, USA.
Abstract:
Ehrlichia chaffeensis is an obligatory intracellular bacterium that infects monocytes and macrophages, and causes human monocytic ehrlichiosis, an emerging life-threatening infectious disease. Ehrlichia translocated factor-1 (Etf-1), a type IV secretion system effector, is essential for Ehrlichia infection of host cells. Etf-1 translocates to mitochondria to block host apoptosis; furthermore, it can bind Beclin 1 (ATG6) to induce cellular autophagy and localize to E. chaffeensis-inclusion membrane to obtain host-cell cytoplasmic nutrients. In this study, we screened a synthetic library of over 320,000 cell-permeable macrocyclic peptides, which consist of an ensemble of random peptide sequences in the first ring and a small family of cell-penetrating peptides in the second ring, for Etf-1 binding. Library screening followed by hit optimization identified multiple Etf-1-binding peptides (with K D values of 1-10 μM) that efficiently enter the cytosol of mammalian cells. Peptides B7, C8, B7-131-5, B7-133-3, and B7-133-8 significantly inhibited Ehrlichia infection of THP-1 cells. Mechanistic studies revealed that peptide B7 and its derivatives inhibited the binding of Etf-1 to Beclin 1, and Etf-1 localization to E. chaffeensis-inclusion membranes, but not Etf-1 localization to the mitochondria. Our results not only affirm the critical role of Etf-1 functions in E. chaffeensis infection, but also demonstrate the feasibility of developing macrocyclic peptides as powerful chemical probes and potential treatment of diseases caused by Ehrlichia and other intracellular pathogens.
Insights
Researchers developed macrocyclic peptides that target Ehrlichia translocated factor-1 (Etf-1), inhibiting Ehrlichia chaffeensis infection by blocking key bacterial functions. These peptides show potential for treating infectious diseases.
Area of Science:
- Microbiology
- Molecular Biology
- Drug Discovery
Background:
- * Ehrlichia chaffeensis causes human monocytic ehrlichiosis, a serious infectious disease.
- * Ehrlichia* translocated factor-1 (Etf-1) is crucial for bacterial infection, manipulating host cell processes like apoptosis and autophagy.
- * Etf-1 targets mitochondria, Beclin 1, and the *E. chaffeensis*-inclusion membrane to facilitate infection.
Purpose of the Study:
- * To identify and characterize novel macrocyclic peptides that bind to Etf-1.
- * To evaluate the efficacy of these peptides in inhibiting *E. chaffeensis* infection.
- * To elucidate the mechanism by which these peptides interfere with Etf-1 function.
Main Methods:
- * Screening of a large library (>320,000) of cell-permeable macrocyclic peptides for Etf-1 binding.
- * Hit optimization to identify high-affinity binders (1-10 μM KD).
- * Assessing peptide inhibition of *E. chaffeensis* infection in THP-1 cells and analyzing Etf-1 interactions.
Main Results:
- * Multiple Etf-1-binding macrocyclic peptides were identified, capable of entering host cells.
- * Peptides B7 and its derivatives significantly inhibited *E. chaffeensis* infection.
- * These peptides blocked Etf-1 binding to Beclin 1 and its localization to the inclusion membrane, but not mitochondrial localization.
Conclusions:
- * Etf-1 plays a vital role in *E. chaffeensis* pathogenesis.
- * Macrocyclic peptides are effective chemical probes for studying Etf-1.
- * Developed peptides represent potential therapeutic agents against *Ehrlichia* and other intracellular pathogens.
Related Concept Videos
Bacterial Phylum Chlamydiae
Chemotaxis in E. coli


